<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of predominantly antibody deficiencies (category III inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of predominantly antibody deficiencies (category III inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of predominantly antibody deficiencies (category III inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1">Immunoglobulin</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells, agammaglobulinemia</td> </tr> <tr> <td class="indent1">BTK deficiency, XL agammaglobulinemia (XLA)</td> <td>Bruton tyrosine kinase (<em>BTK</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300300" target="_blank">300300</a></td> <td>All isotypes decreased in major of patients; some patients have detectable immunoglobulins</td> <td>Severe bacterial infections, normal numbers of pro-B cells</td> </tr> <tr> <td class="indent1">Mu heavy-chain deficiency</td> <td>Immunoglobulin heavy constant mu (<em>IGHM</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147020" target="_blank">147020</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections normal numbers of pro-B cells</td> </tr> <tr> <td class="indent1">Lambda 5 deficiency</td> <td>Immunoglobulin lambda-like polypeptide 1 (<em>IGLL1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/146770" target="_blank">146770</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections, normal numbers of pro-B cells</td> </tr> <tr> <td class="indent1">Immunoglobulin alpha deficiency</td> <td>CD79a molecule (<em>CD79A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/112205" target="_blank">112205</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections, normal numbers of pro-B cells</td> </tr> <tr> <td class="indent1">Immunoglobulin beta deficiency</td> <td>CD79b molecule (<em>CD79B</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147245" target="_blank">147245</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections, normal numbers of pro-B cells</td> </tr> <tr> <td class="indent1">BLNK deficiency</td> <td>B cell linker (<em>BLNK</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/604515" target="_blank">604515</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections, normal numbers of pro-B cells</td> </tr> <tr> <td class="indent1">p110 delta deficiency</td> <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (<em>PIK3CD</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602839" target="_blank">602839</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections, autoimmune complications (IBD)</td> </tr> <tr> <td class="indent1">p85 deficiency</td> <td>Phosphoinositide-3-kinase regulatory subunit 1 (<em>PIK3R1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615214" target="_blank">615214</a></td> <td>All isotypes decreased</td> <td>Severe bacterial infections, cytopenias, decreased or absent pro-B cells</td> </tr> <tr> <td class="indent1" rowspan="2">E47 transcription factor deficiency</td> <td rowspan="2">Transcription factor 3 (<em>TCF3</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616941" target="_blank">616941</a></td> <td>All isotypes decreased</td> <td>Recurrent bacterial infections</td> </tr> <tr> <td>AR</td> <td><a href="https://www.omim.org/entry/147141" target="_blank">147141</a></td> <td>All isotypes decreased</td> <td>Severe, recurrent bacterial infections; failure to thrive</td> </tr> <tr> <td class="indent1">SLC39A7 (ZIP7) deficiency</td> <td>Solute carrier family 39 member 7 (<em>SLC39A7</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/601416" target="_blank">601416</a></td> <td>All isotypes decreased</td> <td>Early-onset infections, blistering dermatosis, failure to thrive, thrombocytopenia</td> </tr> <tr> <td class="indent1">Hoffman syndrome/TOP2B deficiency</td> <td>DNA topoisomerase II beta (<em>TOP2B</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/126431" target="_blank">126431</a></td> <td>All isotypes decreased</td> <td>Recurrent infections, facial dysmorphism, limb anomalies</td> </tr> <tr> <td class="indent1">FNIP1 deficiency</td> <td>Folliculin interacting protein 1 (<em>FNIP1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619705" target="_blank">619705</a></td> <td>All isotypes decreased</td> <td>Early-onset recurrent infections, bronchiectasis, fibrosis, interstitial pneumoniae, neutropenia (severe or intermittent, Crohn disease (1 patient), congenital heart defects, muscular hypotonia, developmental delay</td> </tr> <tr> <td class="indent1">PU1 deficiency</td> <td>Spi-1 proto-oncogene (<em>SPI1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/619707" target="_blank">619707</a></td> <td>All isotypes decreased</td> <td>Sinopulmonary infections with encapsulated bacteria, viral infections</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Severe reduction in at least 2 serum immunoglobulin isotypes with normal or low number of B cell, CVID phenotype</td> </tr> <tr> <td class="indent1">CVID with no gene defect specified</td> <td>Unknown</td> <td>Variable</td> <td> </td> <td>Low IgG and IgA and/or IgM</td> <td>Clinical phenotypes vary; most have recurrent infections; some have polyclonal lymphoproliferation, autoimmune cytopenias, and/or granulomatous disease</td> </tr> <tr> <td class="indent1" rowspan="2">Activated p110 delta syndrome (APDS)</td> <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (<em>PIK3CD</em>) GOF</td> <td>AD</td> <td><a href="https://www.omim.org/entry/615513" target="_blank">615513</a> (APDS1)</td> <td>Normal/increased IgM; reduced IgG and IgA</td> <td>Severe bacterial infections, reduced memory B cells and increased transitional B cells, EBV and/or CMV viremia, lymphadenopathy/splenomegaly, autoimmunity, lymphoproliferation, lymphoma</td> </tr> <tr> <td>Phosphoinositide-3-kinase regulatory subunit 1 (<em>PIK3R1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616005" target="_blank">616005</a> (APDS2)</td> <td>Normal/increased IgM; reduced IgG and IgA</td> <td>Severe bacterial infections, reduced memory B cells and increased transitional B cells, lymphadenopathy/splenomegaly, lymphoproliferation, lymphoma, developmental delay</td> </tr> <tr> <td class="indent1">PTEN deficiency (LOF)</td> <td>Phosphatase and tensin homolog (<em>PTEN</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/158350" target="_blank">158350</a></td> <td>Normal/decreased</td> <td>Recurrent infections, lymphoproliferation, autoimmunity, developmental delay</td> </tr> <tr> <td class="indent1">CD19 deficiency</td> <td>CD19 molecule (<em>CD19</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/107265" target="_blank">107265</a></td> <td>Low IgG and IgA and/or IgM</td> <td>Recurrent infections, may have glomerulonephritis</td> </tr> <tr> <td class="indent1">CD81 deficiency</td> <td>CD81 molecule (<em>CD81</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/186845" target="_blank">186845</a></td> <td>Low IgG; low or normal IgA and IgM</td> <td>Recurrent infections, may have glomerulonephritis (CD81 mutation abolishes expression of CD19, thereby phenocopying CD19 mutations)</td> </tr> <tr> <td class="indent1">CD20 deficiency</td> <td>Membrane spanning 4-domains A1 (<em>MS4A1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/112210" target="_blank">112210</a></td> <td>Low IgG; normal or elevated IgM and IgA</td> <td>Recurrent infections</td> </tr> <tr> <td class="indent1">CD21 deficiency</td> <td>Complement C3d receptor 2 (<em>CR2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/120650" target="_blank">120650</a></td> <td>Low IgG; impaired anti-pneumococcal response</td> <td>Recurrent infections</td> </tr> <tr> <td class="indent1">TACI deficiency*</td> <td>TNF receptor superfamily member 13B (<em>TNFRSF13B</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/604907" target="_blank">604907</a></td> <td>Low IgG and IgA and/or IgM</td> <td>Variable clinical expression nand penetrance for monoallelic variants</td> </tr> <tr> <td class="indent1">BAFF receptor deficiency</td> <td>TNF receptor superfamily member 13C (<em>TNFRSF13C</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606269" target="_blank">606269</a></td> <td>Low IgG and IgM</td> <td>Variable clinical expression</td> </tr> <tr> <td class="indent1">TWEAK deficiency</td> <td>TNF superfamily member 12 (<em>TNFSF12</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/602695" target="_blank">602695</a></td> <td>Low IgM and IgA; lack of anti-pneumococcal antibody</td> <td>Pneumonia, bacterial infections, warts, thrombocytopenia, neutropenia</td> </tr> <tr> <td class="indent1">TRNT1 deficiency</td> <td>tRNA nucleotidyl transferase 1 (<em>TRNT1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/612907" target="_blank">612907</a></td> <td>B cell deficiency and hypogammaglobulinemia</td> <td>Congenital sideroblastic anemia, deafness, developmental delay</td> </tr> <tr> <td class="indent1">NFKB1 deficiency</td> <td>Nuclear factor kappa B subunit 1 (<em>NFKB1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/164011" target="_blank">164011</a></td> <td>Normal or low IgG, IgA, and IgM; low or normal B cells; low memory B cells</td> <td>Recurrent sinopulmonary infections, COPD, EBV proliferation, autoimmune cytopenias, alopecia and autoimmune thyroiditis</td> </tr> <tr> <td class="indent1">NFKB2 deficiency</td> <td>Nuclear factor kappa B subunit 2 (<em>NFKB2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/615577" target="_blank">615577</a></td> <td>Low serum IgG, IgA, and IgM; low B cell numbers</td> <td>Recurrent sinopulmonary infections, alopecia and endocrinopathies</td> </tr> <tr> <td class="indent1">IKAROS deficiency</td> <td>IKAROS family zinc finger 1 (<em>IKZF1</em>)</td> <td>AD (haploinsufficiency)</td> <td><a href="https://www.omim.org/entry/603023" target="_blank">603023</a></td> <td>Low IgG, IgA, and IgM; low or normal B cells; B cells and immunoglobulin levels reduce with age</td> <td>Decreased pro-B cells, recurrent sinopulmonary infections, increased risk of ALL, autoimmunity, CVID phenotype</td> </tr> <tr> <td class="indent1">IRF2BP2 deficiency</td> <td>Interferon regulatory factor 2 binding protein 2 (<em>IRF2BP2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/615332" target="_blank">615332</a></td> <td>Hypogammaglobulinemia; absent IgA</td> <td>Recurrent infections, possible autoimmunity and inflammatory disease</td> </tr> <tr> <td class="indent1">ATP6AP1 deficiency</td> <td>ATPase H+ transporting accessory protein 1 (<em>ATP6AP1</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300972" target="_blank">300972</a></td> <td>Variable immunoglobulin findings</td> <td>Hepatopathy, leukopenia, low copper</td> </tr> <tr> <td class="indent1">ARHGEF1 deficiency</td> <td>Rho guanine nucleotide exchange factor 1 (<em>ARHGEF1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618459" target="_blank">618459</a></td> <td>Hypogammaglobulinemia; lack of antibody</td> <td>Recurrent infections, bronchiectasis</td> </tr> <tr> <td class="indent1">SH3KBP1 (CIN85) deficiency</td> <td>SH3 domain containing kinase binding protein 1 (<em>SH3KBP1</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300310" target="_blank">300310</a></td> <td>IgM and IgG deficiency; loss of antibody</td> <td>Severe bacterial infections</td> </tr> <tr> <td class="indent1">SEC61A1 deficiency</td> <td>SEC61 translocon subunit alpha 1 (<em>SEC61A1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/609213" target="_blank">609213</a></td> <td>Hypogammaglobulinemia</td> <td>Severe recurrent respiratory tract infections</td> </tr> <tr> <td class="indent1">RAC2 deficiency</td> <td>Rac family small GTPase 2 (<em>RAC2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602049" target="_blank">602049</a></td> <td>Low IgG, IgA, and IgM; low or normal B cells; reduced antibody responses following vaccination</td> <td>Recurrent sinopulmonary infections, selective IgA deficiency, poststreptococcal glomerulonephritis, urticaria</td> </tr> <tr> <td class="indent1">Mannosyl-oligosaccharide glucosidase deficiency</td> <td>Mannosyl-oligosaccharide glucosidase (<em>MOGS</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/601336" target="_blank">601336</a></td> <td>Low IgG, IgA, and IgM; increased B cells; poor antibody responses following vaccination</td> <td>Bacterial and viral infections, severe neurologic disease; also known as CDG-IIb</td> </tr> <tr> <td class="indent1">PIK3CG deficiency</td> <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (<em>PIK3CG</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619802" target="_blank">619802</a></td> <td>Reduced memory B cells; hypogammaglobulinemia</td> <td>Recurrent infections, cytopenia/lymphopenia, eosinophilia, splenomegaly, lymphadenopathy, HLH-like</td> </tr> <tr> <td class="indent1">BOB1 deficiency</td> <td>POU class 2 homeobox associating factor 1 (<em>POU2AF1</em>)</td> <td>AR</td> <td> </td> <td>Reduced memory B cells; agammaglobulinemia</td> <td>Recurrent respiratory infections, possible chronic viral infection of CNS with progressive tetraparesia</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells, hyper-IgM</td> </tr> <tr> <td class="indent1" rowspan="2">AID deficiency</td> <td rowspan="2">Activation-induced cytidine deaminase (<em>AICDA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605258" target="_blank">605258</a></td> <td>IgG and IgA decreased; IgM increased; normal memory B cell but lacking somatic hypermutation</td> <td>Bacterial infections, enlarged lymph nodes and germinal centers, autoimmunity</td> </tr> <tr> <td>AD</td> <td><a href="https://www.omim.org/entry/605257" target="_blank">605257</a></td> <td>IgG absent or decreased; IgA undetected; IgM increased; normal memory B cells with intact somatic hypermutation</td> <td>Bacterial infections, enlarged lymph nodes and germinal centers, mutations uniquely localize to the nuclear export signal</td> </tr> <tr> <td class="indent1">UNG deficiency</td> <td>Uracil DNA glycosylase (<em>UNG</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/191525" target="_blank">191525</a></td> <td>IgG and IgA decreased; IgM increased</td> <td>Enlarged lymph nodes and germinal centers</td> </tr> <tr> <td class="indent1">INO80 deficiency</td> <td>INO80 complex ATPase subunit (<em>INO80</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610169" target="_blank">610169</a></td> <td>IgG and IgA decreased; IgM increased</td> <td>Severe bacterial infections</td> </tr> <tr> <td class="indent1">MSH6 deficiency</td> <td>MutS homolog 6 (<em>MSH6</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/600678" target="_blank">600678</a></td> <td>Variable IgG defects; increased IgM in some; normal B cells; low switched memory B cells; immunoglobulin class-switch recombination and somatic hypermutation defects</td> <td>Family or personal history of cancer</td> </tr> <tr> <td class="indent1">CTNNBL1 deficiency</td> <td>Catenin beta-like 1 (<em>CTNNBL1</em>)</td> <td>AR</td> <td> </td> <td>Reduced memory B cells; immunoglobulin class-switch recombination an somatic hypermutation defects; progressive hypogammaglobulinemia</td> <td>CVID, autoimmune cytopenias, recurrent infections, hyperplastic germinal centers</td> </tr> <tr> <td class="indent1">APRIL deficiency</td> <td>TNF superfamily member 13 (<em>TNFSF13</em>)</td> <td>AR</td> <td> </td> <td>Normal total B cell counts; reduced memory B cells; hypogammaglobulinemia</td> <td>CVID, chronic but mild infections, alopecia areata</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Isotype, light chain, or functional deficiencies with generally normal numbers of B cell</td> </tr> <tr> <td class="indent1">Immunoglobulin heavy-chain mutations and deletions</td> <td>Mutation or chromosomal deletion at 14q32</td> <td>AR</td> <td> </td> <td>One or more IgG and/or IgA subclasses as well as IgE may be absent</td> <td>May be asymptomatic</td> </tr> <tr> <td class="indent1">Kappa chain deficiency</td> <td>Immunoglobulin kappa constant (<em>IGKC</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147200" target="_blank">147200</a></td> <td>All immunoglobulins have lambda light chain</td> <td>Asymptomatic</td> </tr> <tr> <td class="indent1">Isolated IgG subclass deficiency</td> <td>Unknown</td> <td>Unknown</td> <td> </td> <td>Reduction in one or more IgG subclass</td> <td>Usually asymptomatic; a minority may have poor antibody response to specific and recurrent viral/bacterial infections</td> </tr> <tr> <td class="indent1">IgG subclass deficiency with IgA deficiency</td> <td>Unknown</td> <td>Unknown</td> <td> </td> <td>Reduced IgA with decreased in one or more IgG subclass</td> <td>Recurrent bacterial infections; may be asymptomatic</td> </tr> <tr> <td class="indent1">Selective IgA deficiency</td> <td>Unknown</td> <td>Unknown</td> <td> </td> <td>Absent IgA with other isotypes normal; normal subclasses and specific antibodies</td> <td>May be asymptomatic; bacterial infections; autoimmunity mildly increased</td> </tr> <tr> <td class="indent1">Specific antibody deficiency with normal immunoglobulin levels and normal B cells</td> <td>Unknown</td> <td>Unknown</td> <td> </td> <td>Normal</td> <td>Reduced ability to produce antibodies to specific antigens</td> </tr> <tr> <td class="indent1">Transient hypogammaglobulinemia of infancy</td> <td>Unknown</td> <td>Unknown</td> <td> </td> <td>IgG and IgA decreased</td> <td>Normal ability to produce antibodies to vaccine antigens, usually not associated with significant infections</td> </tr> <tr> <td class="indent1">CARD11 GOF</td> <td>Caspase recruitment domain family member 11 (<em>CARD11</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/616452" target="_blank">616452</a></td> <td>Polyclonal B cell lymphocytosis due to constitutive NFkB activation</td> <td>Splenomegaly, lymphadenopathy, poor vaccine response</td> </tr> <tr> <td class="indent1">Selective IgM deficiency</td> <td>Unknown</td> <td>Unknown</td> <td> </td> <td>Absent serum IgM</td> <td>Pneumococcal/bacterial</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of mutant genes in table: 45. CVID disorders include several clinical and laboratory phenotypes that may be caused by distinct genetic and/or environmental factors. Some patients with CVID and no known genetic defect have markedly reduced numbers of B cells as well as hypogammaglobulinemia. Identification of causal variants can assist in defining treatment. In addition to monogenic causes on this table, a small minority of patients with X-linked lymphoproliferative disease, WHIM syndrome, ICF, VODI, thymoma with immunodeficiency (Good syndrome), or myelodysplasia are first seen by an immunologist because of recurrent infections, hypogammaglobulinemia, and normal or reduced number of B cells.</div><div class="graphic_footnotes"><p>IUIS: International Union of Immunological Societies; 
    XL: X linked; 
    AR: autosomal recessive; 
    IBD: inflammatory bowel disease; 
    AD: autosomal dominant; 
    ZIP7: zinc transporter 7; 
    DNA: deoxyribonucleic acid; 
    PU1: hematopoietic transcription factor PU.1; 
    CVID: common variable immunodeficiency; 
    IgG: immunoglobulin G; 
    IgA: immunoglobulin A; 
    IgM: immunoglobulin M; GOF: gain of function; 
    EBV: Epstein-Barr virus; 
    CMV: cytomegalovirus; 
    LOF: loss of function;
    CD: cluster of differentiation; 
    TACI: transmembrane activator and calcium modulator and cyclophilin ligand interactor; TNF: tumor necrosis factor; 
    BAFF: B cell activating factor; 
    TWEAK: TNF-related weak inducer of apoptosis; 
    tRNA: transfer ribonucleic acid; 
    COPD: chronic obstructive pulmonary disease; 
    ALL: acute lymphoblastic leukemia; 
    CIN85: Cbl-interacting 85 kDa protein; 
    CDG-IIb: congenital disorder of glycosylation type IIb; 
    HLH: hemophagocytic lymphohistiocytosis; 
    BOB1: B cell-specific octamer binding protein 1; 
    CNS: central nervous system; 
    AID: activation-induced cytidine deaminase; 
    APRIL: A proliferation-inducing ligand; 
    IgE: immunoglobulin E; NFkB: nuclear factor kappa B; 
    WHIM: warts, hypogammaglobulinemia, infections, myelokathexis; 
    ICF: immunodeficiency with centromeric instability and facial anomalies; 
    VODI: veno-occlusive disease with immunodeficiency.</p>
    
    * Heterozygous variants in TNFRSF13B have been detected in healthy individuals; thus, such variants are likely to be disease modifying rather than disease causing.</div><div class="graphic_reference">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright © 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 139944 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
